{"schema_version":"secwatch.filing_event.v1","accession":"0000313616-24-000106","form_type":"8-K","ticker":"DHR","cik":"0000313616","company_name":"DANAHER CORP /DE/","filed_at":"2024-04-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:21.517241+00:00","generated_at":"2026-06-03T12:36:45.911953+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Danaher Q1 2024 beats expectations with $5.8B revenue, $1.92 adj EPS","bullets":["Net earnings $1.1B, diluted EPS $1.45; adjusted diluted EPS $1.92.","Revenue $5.8B, down 2.5% YoY; core revenue down 4.0%.","Operating cash flow $1.7B; free cash flow $1.4B.","CEO reports improving bioprocessing order trends and market share gains in molecular diagnostics at Cepheid.","Q2 core revenue expected down mid-single digits; full year 2024 core revenue expected down low-single digits."],"urls":{"canonical":"https://secwatch.observer/filing/0000313616-24-000106","json":"https://secwatch.observer/filing/0000313616-24-000106.json","markdown":"https://secwatch.observer/filing/0000313616-24-000106.md","text":"https://secwatch.observer/filing/0000313616-24-000106.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/313616/000031361624000106/0000313616-24-000106-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/313616/000031361624000106/dhr-20240423.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T12:36:45.911953+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"31fa24b6f4acb8c635be8438d59ae3217ae7c118","claim":"DANAHER CORP /DE/ reported the quarter ended March 29, 2024 results: revenue $5.8 billion, net income $1.1 billion, EPS $1.45 per diluted common share.","evidence_excerpt":"earnings were $1.1 billion, or $1.45 per diluted common share and non-GAAP adjusted diluted net earnings per common share were $1.92. • Revenues decreased 2.5% year-over-year to $5.8 billion and non-GAAP core revenue decreased 4.0%. • Operating cash flow was $1.7 billion and non-GAAP free cash flow was $1.4 billion. Rainer M. Blair, President and Chief Executive","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/313616/000031361624000106/0000313616-24-000106-index.htm","confidence":0.99,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 29, 2024"},{"label":"Revenue","value":"$5.8 billion"},{"label":"Net income","value":"$1.1 billion"},{"label":"EPS","value":"$1.45 per diluted common share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}